Boston Scientific Corporation announced preliminary unaudited sales for the fourth quarter and full year of 2019. For the quarter, the company reported net sales of $2.90 billion against $2.56 billion a year ago.

For the year, the company reported net sales of $10.74 billion against $9.82 billion a year ago.

The company estimates that it will exceed its previously issued guidance for earnings of $0.22 to $0.25 for the fourth quarter and $0.72 to $0.75 per share for the full year 2019, on a GAAP per share basis, primarily due to a significant non-cash tax benefit arising from an intra-entity asset transfer of intellectual property completed in the fourth quarter of 2019.